Erythropoiesis stimulating agents: A personal journey

Journal of the National Cancer Institute

Volumn 105, Issue 14, 2013, Pages 999-1001

  Leyland Jones, Brian ^a  

^a Edith Sanford Breast Cancer Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; CYCLOPHOSPHAMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CYTOPATHOGENIC EFFECT; DRUG MECHANISM; EDITORIAL; HEMOGLOBIN BLOOD LEVEL; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIOSENSITIVITY; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; TISSUE OXYGENATION; TREATMENT OUTCOME; TUMOR IMMUNITY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; RECOMBINANT PROTEINS;

EID: 84880561454     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt171     Document Type: Editorial

References (26)

1. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56(19): p. 4509-15. (Pubitemid 26330463)
2. Hockel M, Schlenger K, Hockel S, Aral B, Schaffer U, Vaupel P. Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer. 1998;79(4):365-369. (Pubitemid 28359734)
3. Thews O, Kelleher DK, Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res. 2001;61(4)1358-1361. (Pubitemid 34292556)
4. Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci U S A. 2001;98(9):5181-5186. (Pubitemid 32397103)
5. Vaupel P, Kelleher DK. Tumor hypoxia: pathophysiology, clinical significance and therapeutic perspectives: Wissenschaftliche Verlagsgesellschaft; 1999. (ISBN: 3804717330)
6. Stuben G, Thews O, Pottgen C, Knuhmann K, Vaupel P, Stuschke M. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol. 2001;127(6):346-350. (Pubitemid 32453676)
7. Kelleher DK, Mattheinsen U, Thews O, Vaupel P. Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res. 1996;56(20):4728-4734. (Pubitemid 26338077)
8. Rosti V, Pedrazzoli P, Ponchio L, et al. Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica. 1993;78(4):208-212. (Pubitemid 23323068)
9. Silver D F, Piver MS. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect. Gynecol Oncol. 1999;73(2):280-284. (Pubitemid 29215744)
10. Wollman Y, Westphal G, Blum M, et al. The effect of human recombinant erythropoietin on the growth of a human neuroblastoma cell line. Life Sci. 1996;59(4):315-322. (Pubitemid 26232869)
11. Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys. 2001;50(3):705-715. (Pubitemid 32519598)
12. Littlewood TJ, Bajetta E, Nortier JWR, Vercamen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Resuts of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 19(11):2865-2874.
13. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23(25):5960-5972.
14. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 362(9392):1255-1260.
15. Leyland-Jones B, BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003;4(8):459-460. (Pubitemid 37009952)
16. Tonelli M, Hemmelgarn B, Reiman T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ. 2009;180(11):E62-E71.
17. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010;102(2):301-315.
18. Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12:CD003407.
19. Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B, et al. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer. 2012;106(7):1249-1258.
20. Oncologic Drugs Advisory Committee (ODAC) Briefing Document for the 13 March 2008 Meeting: Epoetin alfa (Epogen®/PROCRIT®) and darbepoetin alfa (Aranesp®). Amgen Inc. 7 February 2008. Available at: http://www.fda.gov/ ohrms/dockets/ac/08/briefing/2008-4345b2-00-FDA-index.htm
21. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373(9674):1532-1542.
22. Paladini L. Meta-analysis of trials performed within label. Blood. 2008; 112(11):abstract 1305.
23. Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2006;3:CD003407.
24. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98(10):708-714. (Pubitemid 43821788)
25. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299(8):914-924. (Pubitemid 351397066)
26. Moebus V, Jackisch C, Schneeweiss A. Adding epoetin alfa to intense dosedense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst. 2013;105(14):1018-1026.